(Q36752667)

16 August 2017

1 reference

title

Should pharmacogenomic studies be required for new drug approval? (English)

1 reference

16 August 2017

0 references

1 reference

Relling MV

1

1 reference

16 August 2017

Hoffman JM

series ordinal

2

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

Clinical Pharmacology & Therapeutics

16 August 2017

published in

1 reference

16 August 2017

volume

81

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

425-428

1 reference

Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100097

Pharmacogenetic perspectives gained from twin and family studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100097

Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100097

Genome-wide discovery of loci influencing chemotherapy cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100097

Characterization of single-nucleotide polymorphisms in coding regions of human genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100097

The price of innovation: new estimates of drug development costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100097

Incidence and preventability of adverse drug events among older persons in the ambulatory setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100097

Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100097

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100097

How Vioxx is changing US drug regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100097

Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100097

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100097

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100097

Cancer pharmacogenomics: current and future applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100097

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100097

Pharmacogenetics and adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100097

Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100097

Pharmacogenetics and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100097

National health spending in 2004: recent slowdown led by prescription drug spending

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100097

The NIH budget and the future of biomedical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100097

Mutagen sensitivity has high heritability: evidence from a twin study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100097

7 January 2021

A DNA Polymorphism Discovery Resource for Research on Human Genetic Variation: Table 1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100097

7 January 2021

Clinical application of pharmacogenetics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100097

7 January 2021

Evaluating drug effects in the post-Vioxx world: there must be a better way

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100097

7 January 2021

The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100097

7 January 2021

Methylation pharmacogenetics: thiopurine methyltransferase as a model system

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100097

7 January 2021

Public and private sector contributions to the discovery and development of "impact" drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100097

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100097

1 reference

16 August 2017

1 reference